Lancet·· 1 day agoPickScore89
Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.
In brief
In two randomised phase 3 trials, REMODEL-1 and REMODEL-2, remibrutinib significantly reduced the annualised relapse rate in relapsing multiple sclerosis compared with teriflunomide.
Why it matters
Two randomised phase 3 trials directly compare remibrutinib with teriflunomide and report ARR, rate ratio intervals and discontinuation data for efficacy and safety assessment.
Source: Lancet · doi.org